STOCK TITAN

[144] Ginkgo Bioworks Holdings, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

DNA filed a Form 144 notice for a proposed sale of 1,312 shares of Class A common stock with an aggregate market value of $17,907.89, with an approximate sale date of 10/21/2025 on the NYSE through Fidelity Brokerage Services LLC.

The shares were acquired on 10/16/2025 via restricted stock vesting as compensation. In the past three months, Steve Coen sold 310 shares for gross proceeds of $3,842.79. Shares outstanding were 47,089,598; this is a baseline figure, not the amount being offered.

DNA ha presentato una nota Form 144 per la vendita proposta di 1.312 azioni ordinarie di Classe A per un valore di mercato complessivo di $17.907,89, con una data di vendita approssimativa 21/10/2025 sul NYSE tramite Fidelity Brokerage Services LLC.

Le azioni sono state acquisite il 16/10/2025 tramite vesting di azioni limitate come compenso. Nell'ultimo trimestre, Steve Coen ha venduto 310 azioni per proventi lordi di $3.842,79. Le azioni in circolazione erano 47.089.598; questa è una cifra di base, non l'importo offerto.

DNA presentó un aviso Form 144 para la venta propuesta de 1,312 acciones ordinarias de Clase A con un valor de mercado total de $17,907.89, con una fecha de venta aproximada de 21/10/2025 en la NYSE a través de Fidelity Brokerage Services LLC.

Las acciones fueron adquiridas el 16/10/2025 mediante vesting de acciones restringidas como compensación. En los últimos tres meses, Steve Coen ha vendido 310 acciones por ingresos brutos de $3,842.79. Las acciones en circulación eran 47,089,598; esta es una cifra base, no la cantidad que se ofrece.

DNA은() 1,312 주의 클래스 A 보통주의 제안된 매각에 대한 Form 144 공시를 제출했으며, 총 시장 가치는 $17,907.89, 매각 예정일은 대략 2025-10-21이며 NYSE에서 Fidelity Brokerage Services LLC를 통해 진행됩니다.

주식은 보상으로 제한 주식 vesting를 통해 2025-10-16에 취득되었습니다. 지난 3개월 동안 Steve Coen310주를 매도했고 총 수익은 $3,842.79입니다. 발행 주식 수는 47,089,598주였으며; 이는 기본 수치이며 제시된 금액이 아닙니다.

DNA a déposé un avis Form 144 pour la vente proposée de 1 312 actions ordinaires de classe A d'une valeur marchande globale de $17 907,89, avec une date de vente approximative 21/10/2025 sur le NYSE via Fidelity Brokerage Services LLC.

Les actions ont été acquises le 16/10/2025 par vesting d’actions restreintes en tant qu’indemnisation. Au cours des trois derniers mois, Steve Coen a vendu 310 actions pour des produits bruts de $3 842,79. Les actions en circulation étaient 47 089 598; il s’agit d’un chiffre de base, et non du montant offert.

DNA hat eine Form 144-Mitteilung über den vorgeschlagenen Verkauf von 1.312 Stammaktien der Klasse A eingereicht, mit einem Gesamtmarktwert von $17.907,89, voraussichtliches Verkaufsdatum 21.10.2025 an der NYSE über Fidelity Brokerage Services LLC.

Die Aktien wurden am 16.10.2025 über Vesting von Restricted Stock als Vergütung erworben. In den letzten drei Monaten hat Steve Coen 310 Aktien für Bruttoerlöse von $3.842,79 verkauft. Die ausstehenden Aktien betrugen 47.089.598; dies ist eine Basiszahl, nicht der angebotene Betrag.

DNA قدم إشعار Form 144 بخصوص بيع مقترح لـ 1,312 سهماً من عوائدClass A بقيمة سوقية إجمالية قدرها $17,907.89، مع تاريخ بيع تقريبي 21/10/2025 في NYSE عبر Fidelity Brokerage Services LLC.

تم اكتساب الأسهم في 16/10/2025 عن طريق تقاعد الأسهم المقيدة كتعويض. في الثلاثة أشهر الأخيرة، باع Steve Coen 310 أسهم بعوائد إجمالية قدرها $3,842.79. الأسهم القائمة كانت 47,089,598؛ هذه قيمة أساسية، وليست المبلغ المعروض.

DNA 提交了 Form 144 通知,提议出售 1,312 股 A 类普通股,总市值为 $17,907.89,大致出售日期为 2025/10/21,在 NYSE 通过 Fidelity Brokerage Services LLC 完成。

这些股票于 2025/10/16 通过受限股票归属作为薪酬而取得。在过去三个月里,Steve Coen 已出售 310 股,毛收入为 $3,842.79。流通股数为 47,089,598;这是基线数,不是正在要约的数量。

Positive
  • None.
Negative
  • None.

DNA ha presentato una nota Form 144 per la vendita proposta di 1.312 azioni ordinarie di Classe A per un valore di mercato complessivo di $17.907,89, con una data di vendita approssimativa 21/10/2025 sul NYSE tramite Fidelity Brokerage Services LLC.

Le azioni sono state acquisite il 16/10/2025 tramite vesting di azioni limitate come compenso. Nell'ultimo trimestre, Steve Coen ha venduto 310 azioni per proventi lordi di $3.842,79. Le azioni in circolazione erano 47.089.598; questa è una cifra di base, non l'importo offerto.

DNA presentó un aviso Form 144 para la venta propuesta de 1,312 acciones ordinarias de Clase A con un valor de mercado total de $17,907.89, con una fecha de venta aproximada de 21/10/2025 en la NYSE a través de Fidelity Brokerage Services LLC.

Las acciones fueron adquiridas el 16/10/2025 mediante vesting de acciones restringidas como compensación. En los últimos tres meses, Steve Coen ha vendido 310 acciones por ingresos brutos de $3,842.79. Las acciones en circulación eran 47,089,598; esta es una cifra base, no la cantidad que se ofrece.

DNA은() 1,312 주의 클래스 A 보통주의 제안된 매각에 대한 Form 144 공시를 제출했으며, 총 시장 가치는 $17,907.89, 매각 예정일은 대략 2025-10-21이며 NYSE에서 Fidelity Brokerage Services LLC를 통해 진행됩니다.

주식은 보상으로 제한 주식 vesting를 통해 2025-10-16에 취득되었습니다. 지난 3개월 동안 Steve Coen310주를 매도했고 총 수익은 $3,842.79입니다. 발행 주식 수는 47,089,598주였으며; 이는 기본 수치이며 제시된 금액이 아닙니다.

DNA a déposé un avis Form 144 pour la vente proposée de 1 312 actions ordinaires de classe A d'une valeur marchande globale de $17 907,89, avec une date de vente approximative 21/10/2025 sur le NYSE via Fidelity Brokerage Services LLC.

Les actions ont été acquises le 16/10/2025 par vesting d’actions restreintes en tant qu’indemnisation. Au cours des trois derniers mois, Steve Coen a vendu 310 actions pour des produits bruts de $3 842,79. Les actions en circulation étaient 47 089 598; il s’agit d’un chiffre de base, et non du montant offert.

DNA hat eine Form 144-Mitteilung über den vorgeschlagenen Verkauf von 1.312 Stammaktien der Klasse A eingereicht, mit einem Gesamtmarktwert von $17.907,89, voraussichtliches Verkaufsdatum 21.10.2025 an der NYSE über Fidelity Brokerage Services LLC.

Die Aktien wurden am 16.10.2025 über Vesting von Restricted Stock als Vergütung erworben. In den letzten drei Monaten hat Steve Coen 310 Aktien für Bruttoerlöse von $3.842,79 verkauft. Die ausstehenden Aktien betrugen 47.089.598; dies ist eine Basiszahl, nicht der angebotene Betrag.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does DNA's Form 144 filing propose to sell?

A proposed sale of 1,312 Class A shares with an aggregate market value of $17,907.89.

When is the approximate sale date in the DNA Form 144?

The approximate sale date listed is 10/21/2025.

Which broker and exchange are listed for the proposed DNA sale?

Broker: Fidelity Brokerage Services LLC; Exchange: NYSE.

How were the DNA shares to be sold acquired?

They were acquired on 10/16/2025 via restricted stock vesting as compensation.

Were there recent sales by the filer related to DNA?

Yes. In the past three months, Steve Coen sold 310 shares for $3,842.79.

How many DNA shares are outstanding as referenced in the notice?

The notice lists 47,089,598 shares outstanding.
Ginkgo Bioworks Holdings Inc

NYSE:DNA

DNA Rankings

DNA Latest News

DNA Latest SEC Filings

DNA Stock Data

777.29M
55.40M
6.73%
79.11%
11.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON